Archive for » 十一月, 2008 «

星期日, 十一月 02nd, 2008 | Author:

MONTEREY, CA, USA (UroToday.com) – In his State-of-the-Art talk, Colin Collins discussed biomarkers for prostate cancer (CaP) risk stratification. He asked where genome copy number profiles can predict CaP recurrences. To explore this, his group used array comparative genomic hybridization (CGH) to identify genes mutations. The array data displays gene amplification and losses as topographical data.

星期日, 十一月 02nd, 2008 | Author:

MONTEREY, CA, USA (UroToday.com) – In this session, Christopher P. Evans presented a State-of-the-Art lecture on molecular targets in prostate and renal cancers. Molecular targets in cancer diagnosis and therapy have come to the fore of the oncology field in the last decade. Their identification is rooted in basic science investigation and enhanced knowledge in the fields of genetics, biochemistry, molecular and tumor biology, and pathology, among others.

星期日, 十一月 02nd, 2008 | Author:

UroToday.com – Protocol 30846 of the EORTC-GU Group recruited 234 patients with histologically proven lymph node positive disease (pN1-3) according to the TNM classification of 1992. This included regional but not para-aortic lymph node disease. At the time the study was initiated in 1983, lymph node positive disease was encountered in 20 to 50% of cases that were clinically considered to be eligible for radical prostatectomy or radiotherapy.

星期日, 十一月 02nd, 2008 | Author:

UroToday.com – In 1999, Kim et al. from Baylor College of Medicine reported promising potency results from bilateral interposition of sural nerve grafts after bilateral non nerve sparing radical prostatectomy (RP). Our institution was able to duplicate these findings in the bilateral graft model as well. However, we were not sure how to properly analyze the efficacy of a unilateral nerve sparing plus unilateral non-nerve sparing with and without a unilateral sural nerve graft.

星期日, 十一月 02nd, 2008 | Author:

UroToday.com – This paper reports the results of a saturation biopsy protocol of 36 cores performed on 48 autopsied prostates from deceased men without any past history of prostate cancer. The first 18 cores were taken in the mid peripheral zone (6 cores), the lateral peripheral zone (6 cores) and the central zone (6 cores). An additional set of 18 cores were taken in the same locations, bringing the total number of cores to 36. Autopsied glands were then step-sectioned and analysed.

星期日, 十一月 02nd, 2008 | Author:

CancerCare has announced that despite an overall increase in news reporting on lung cancer, the overall tone of lung cancer media coverage has become significantly more negative. “How the U.S. Media Report on Cancer,” an analysis of lung, breast, colorectal and prostate cancer coverage, was an independent report conducted by CARMA International Inc. for CancerCare; previous analyses were issued in 2000 and 2004.

星期日, 十一月 02nd, 2008 | Author:

Use of cholesterol-lowering statins is associated with a statistically significant decline in prostate specific antigen (PSA) levels, according to a report in the October 28 online issue of the Journal of the National Cancer Institute. Previous studies examined whether statin use was associated with a reduction in prostate cancer risk. The results, however, have been inconsistent. Few studies have examined the association between statins and PSA level.

星期日, 十一月 02nd, 2008 | Author:

An initial independent review of data from a study looking at whether selenium and vitamin E supplements prevented prostate cancer found they had no benefit, taken either together or alone. The review of data from the Selenium and Vitamin E Cancer Prevention Trial (SELECT) was funded by the National Cancer Institute (NCI) in the US and other institutes from the National Institutes of Health in the US.

星期日, 十一月 02nd, 2008 | Author:

Pink is all the rage in October as money and awareness are raised for the most common cancer for women (other than skin cancer) during Breast Cancer Awareness month. But what about some attention for one of the most common cancers in men? prostate cancer is the second leading cause of cancer death in men, according to the American Cancer Society.

星期日, 十一月 02nd, 2008 | Author:

The number of prostate cancer cases is increasing rapidly. Fortunately not all these tumours need to be operated – some are slow growing or indolent. The question remains: how do we reliably establish which tumour is aggressive and which is not? The answer may well be given by the PCA3 (prostate cancer Gene 3) test, a breakthrough in the diagnosis of prostate cancer.